Bacillus anthracis (Anthrax)

Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases

Volumn 2, Issue , 2014, Pages 2391-2409.e2

  Martin, Gregory J ^a,b   Friedlander, Arthur M ^b,c  

^a Office of Medical Services DC   (United States)

^b Uniformed Services University of the Health Sciences   (United States)

^c UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

Anthrax; Bioterrorism; Cutaneous; Gastrointestinal; Inhalational; Meningitis; Nasal swab; Raxibacumab; Remediation; Spores

Indexed keywords

EID: 84924463486     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4557-4801-3.00209-5     Document Type: Chapter

References (226)

1. Dirckx J Virgil on anthrax. Am J Dermatopathol 1981, 3:191-195.
2. Jay V The legacy of Robert Koch. Arch Pathol Lab Med 2001, 125:1148-1149.
3. Carter T The dissemination of anthrax from imported wool: Kidderminster 1900-14. Occup Environ Med 2004, 61:103-107.
4. Bell JH On Anthrax and anthracaemia in wool-sorters, heifers, and sheep. Br Med J 1880, 2:656-657.
5. Abramova F, Grinberg L, Yamplskaya O, Walker D Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proc Natl Acad Sci U S A 1993, 90:2291-2294.
6. Stone R Peering into the shadows: Iraq's bioweapons program. Science 2002, 297:1110-1112.
7. World Health Organization Anthrax Data Site Available at, Accessed January 11, 2013. http://www.vetmed.lsu.edu/whocc/mp_world.htm.
8. Smith K, deVos V, Bryden H, et al. Meso-scale ecology of anthrax in southern Africa: a pilot study of diversity and clustering. J Appl Microbiol 1999, 87:204-207.
9. Smith K, deVos V, Bryden H, et al. Bacillus anthracis: diversity in Kruger National Park. J Clin Microbiol 2000, 38:3780-3784.
10. Sterne M Distribution and economic importance of anthrax. Fed Proc 1967, 26:1493-1495.
11. Davies J A major epidemic of anthrax in Zimbabwe. Cent Afr J Med 1982, 28:291-298.
12. Davies J A major epidemic of anthrax in Zimbabwe: the experience at the Beatrice Road Infectious Diseases Hospital, Harare. Cent Afr J Med 1985, 31:176-180.
13. Munang'andu HM, Banda F, Siamdudaala VM, et al. The effect of seasonal variation on anthrax epidemiology in the upper Zambezi floodplain of western Zambia. J Vet Sci 2012, 13:293-298.
14. Clegg S, Turnbull P, Foggin C, Lindeque P Massive outbreak of anthrax in wildlife in the Malilangwe Wildlife Reserve, Zimbabwe. Vet Rec 2007, 160:113-118.
15. Hugh-Jones M, deVos V Anthrax and wildlife. Rev Sci Tech 2002, 21:359-383.
16. Centers for Disease Control and Prevention Inhalation anthrax associated with dried animal hides-Pennsylvania and New York City, 2006. MMWR Morb Mortal Wkly Rep 2006, 55:280-282.
17. Centers for Disease Control and Prevention Cutaneous anthrax associated with drum making using goat hides from West Africa-Connecticut, 2007. MMWR Morb Mortal Wkly Rep 2008, 57:628-631.
18. Centers for Disease Control and Prevention Gastrointestinal anthrax after an animal-hide drumming event-New Hampshire and Massachusetts, 2009. MMWR Morb Mortal Wkly Rep 2010, 59:872-877.
19. Anaraki S, Addiman S, Nixon G, et al. Investigations and control measures following a case of inhalation anthrax in East London in a drum maker and drummer, October 2008. Euro Surveill 2008, 13:19076.
20. deVos V The ecology of anthrax in the Krueger National Park, South Africa. Salisbury Med Bull (Suppl) 1990, 68:19-23.
21. Palmateer NE, Ramsay CN, Browning L, et al. Anthrax infection among heroin users in Scotland during 2009-2010: a case-control study by linkage to a national drug treatment database. Clin Infect Dis 2012, 55:706-710.
22. Grunow R, Verbeek L, Jacob D, et al. Injection anthrax-a new outbreak in heroin users. Dtsch Arztebl Int 2012, 109:843-848.
23. Health Protection Scotland An outbreak of anthrax among drug users in Scotland, December 2009 to December 2010 December 2011, Health Protection Scotland, Glasgow. http://www.documents.hps.scot.nhs.uk/giz/anthrax-outbreak/anthrax-outbreak-report-2011-12.pdf.
24. American Society for Microbiology, Centers for Disease Control and Prevention, and Association of Public Health Laboratories Sentinel Level Clinical Microbiology Laboratory Guidelines for Suspected Agents of Bioterrorism and Emerging Infectious Diseases-Bacillus anthracis 2010, American Society for Microbiology, Washington, DC.
25. Center for Infectious Disease Research and Policy Anthrax: Clinical Laboratory Testing Available at, Accessed January 21, 2013. http://www.cidrap.umn.edu/cidrap/content/bt/anthrax/biofacts/index.html.
26. Redmond C, Pearce M, Manchee R, Berdal B Deadly relic of the Great War. Nature 1998, 393:747-748.
27. deVos V The isolation of viable and pathogenic Bacillus anthracis organisms from 200 year old bone fragments from the Kruger National Park. Proceedings of the ARC-Onderstepoort OIE International Congress, with WHO Co-sponsorship, on Anthrax, Brucellosis, CBPP, and Clostridial and Mycobacterial Diseases. Berg-en-Dal, Kruger National Park, South Africa, 1998 1998, 22-24. Sigma Press, Pretoria.
28. Glassman H Discussion-industrial inhalation anthrax. Bacteriol Rev 1966, 30:657-659.
29. Gochenour W, Sawyer W, Henderson J, et al. On the recognition and therapy of simian woolsorter's disease. J Hyg 1963, 61:317-322.
30. Henderson D, Peacock S, Belton F Observations on the prophylaxis of experimental pulmonary anthrax in the monkey. J Hyg 1956, 54:28-36.
31. Stanley J, Smith H Purification of factor I and recognition of a third factor of the anthrax toxin. J Gen Microbiol 1961, 26:49-66.
32. Bann JG Anthrax toxin protective antigen-insights into molecular switching from prepore to pore. Protein Sci 2012, 21:1-12.
33. Liu S, Miller-Randolph S, Crown D, et al. Anthrax toxin targeting of myeloid cells through the CMG2 receptor is essential for establishment of Bacillus anthracis infections in mice. Cell Host Microbiol 2010, 8:455-462.
34. Tournier JN, Rossi Paccani S, Quesnel-Hellmann A, Baldari CT Anthrax toxins: a weapon to systematically dismantle the host immune defenses. Mol Aspects Med 2009, 30:456-466.
35. Ghosh CC, Mukherjee A, David S, et al. Impaired function of the Tie-2 receptor contributes to vascular leakage and lethality in anthrax. Proc Natl Acad Sci U S A 2012, 109:10024-10029.
36. Sun C, Fang H, Xie T, et al. Anthrax lethal toxin disrupts intestinal barrier function and causes systemic infections with enteric bacteria. PLoS One 2012, 7.
37. Booth MG, Hood J, Brooks TJG Anthrax infection in drug users. Lancet 2010, 375:1345-1346.
38. World Health Organization Anthrax in Humans and Animals 2008, WHO Press, Geneva. 4th ed.
39. American Society for Microbiology Sentinel Laboratory Guidelines for Suspected Agents of Bioterrorism and Emerging Infections Diseases Packing and Shipping Infectious Substances Available at, Accessed February 12, 2013. http://www.asm.org/index.php/issues/sentinel-laboratory-guidelines.
40. Gold H Anthrax, a report of one hundred seventeen cases. Arch Intern Med 1955, 96:387-396.
41. Doganay M, Metan G, Alp E A review of cutaneous anthrax and its outcome. J Infect Public Health 2010, 3:98-105.
42. Roche K, Chang M, Lazarus H Cutaneous anthrax infection. N Engl J Med 2001, 345:1611.
43. American College of Physicians Anthrax Available at, Accessed January 21, 2013. http://pier.acponline.org/physicians/public/d892/d892.html.
44. De BK, Bragg SL, Sanden GN, et al. A two-component direct fluorescent-antibody assay for rapid identification of Bacillus anthracis. Emerg Infect Dis 2002, 8:1060-1065.
45. Mabry R, Brasky K, Geiger R, et al. Detection of anthrax toxin in the serum of animals infected with Bacillus anthracis by using engineered immunoassays. Clin Vaccine Immunol 2006, 13:671-677.
46. Dauphin LA, Marston CK, Bhullar V, et al. Swab protocol for rapid laboratory diagnosis of cutaneous anthrax. J Clin Microbiol 2012, 50:3960-3967.
47. Hoffmaster AR, Meyer RF, Bowen MD, et al. Evaluation and validation of a real-time polymerase chain reaction assay for rapid identification of Bacillus anthracis. Emerg Infect Dis 2002, 8:1178-1182.
48. Quinn C, Dull P, Semenova V, et al. Immune response to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthrax. J Infect Dis 2004, 190:1228-1236.
49. Hicks CW, Sweeney DA, Cui X, et al. An overview of anthrax infection including the recently identified form of disease in injection drug users. Intensive Care Med 2012, 38:1092-1104.
50. Holty J, Bravata D, Liu H, et al. Systematic review: a century of inhalational anthrax cases from 1900 to 2005. Ann Intern Med 2006, 144:270-280.
51. Macher A Industry-related outbreak of human anthrax, Massachusetts, 1868. Emerg Infect Dis 2002, 8:1182.
52. Plotkin S, Brachman P, Utell M, et al. An epidemic of inhalation anthrax, the first in the twentieth century. Am J Med 1960, 29:992-1001.
53. Norman P, Ray J, Brachman P, et al. Serological testing for anthrax antibodies in workers in a goat hair processing mill. Am J Hyg 1960, 72:32-37.
54. Chakrabarty K, Wu W, Leland Booth J, et al. Human lung innate immune response to Bacillus anthracis spore infection. Infect Immun 2007, 75:3729-3738.
55. Coleman M, Thran B, Morse S, et al. Inhalation anthrax: dose response and risk analysis. Biosec Bioterr 2008, 6:147-159.
56. Lucey D Anthrax. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases 2005, 3618-3624. Churchill Livingstone, Philadelphia. 6th ed. G.L. Mandell, J.E. Bennett, R. Dolin (Eds.).
57. Brookmeyer R, Johnson E, Bollinger R Modeling the optimum duration of antibiotic prophylaxis in an anthrax outbreak. Proc Natl Acad Sci U S A 2003, 100:10129-10132.
58. Vietri NJ, Purcell BK, Tobery SA, et al. A short course of antibiotic treatment is effective in preventing death from experimental inhalational anthrax after discontinuing antibiotics. J Infect Dis 2009, 199:336-341.
59. Mohamed N, Clagett M, Li J A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis: spore challenge. Infect Immun 2005, 73:795-802.
60. Vitale L, Blanset D, Lowy I, et al. Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity. Infect Immun 2006, 74:5840-5847.
61. Migone TS, Subramanian GM, Zhong J, et al. Raxibacumab for the treatment of inhalational anthrax. N Engl J Med 2009, 361:135-144.
62. Fine A, Wong J, Fraser H, et al. Is it influenza or anthrax? A decision analytic approach to the treatment of patients with influenza-like illnesses. Ann Emerg Med 2004, 43:318-328.
63. Borio L, Frank D, Mani V, et al. Death due to bioterrorism-related inhalational anthrax. JAMA 2001, 286:2554-2559.
64. Guarner J, Jernigan J, Shieh W Pathology and pathogenesis of bioterrorism-related inhalational anthrax. Am J Pathol 2003, 163:701-709.
65. Jernigan J, Stephens D, Ashford D, et al. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis 2001, 7:933-943.
66. Sirisanthana T, Brown A Anthrax of the gastrointestinal tract. Emerg Infect Dis 2002, 8:649-651.
67. Beatty M, Ashford D, Griffin P, et al. Gastrointestinal anthrax. Arch Intern Med 2003, 163:2527-2531.
68. Sirisanthana T, Navachareon N, Tharavichitkul P, et al. Outbreak of oral-pharyngeal anthrax: an unusual manifestation of human infection with Bacillus anthracis. Am J Trop Med Hyg 1984, 33:144-150.
69. Doganay M, Almac A, Hanagasi R Primary throat anthrax. Scand J Infect Dis 1986, 18:415-419.
70. Haight T Anthrax meningitis: review of the literature and report of two cases with autopsies. Am J Med Sci 1952, 224:57-69.
71. Sejvar J, Tenover F, Stephens D Management of anthrax meningitis. Lancet Infect Dis 2005, 5:287-295.
72. vanSorge N, Ebrahimi C, McGillivray S Anthrax toxins inhibit neutrophil signaling pathways in brain endothelium and contribute to the pathogenesis of meningitis. PLoS One 2008, 3:e2964.
73. Cleret-Buhot A, Mathieu J, Tournier JN, Quesnel-Hellmann A Both lethal and edema toxins of Bacillus anthracis disrupt the human dendritic cell chemokine network. PLoS One 2012, 7:e43266.
74. Lanska D Anthrax meningoencephalitis. Neurology 2002, 59:327-334.
75. Coker P, Smith K, Hugh-Jones M Antimicrobial susceptibilities of diverse Bacillus anthracis isolates. Antimicrob Agents Chemother 2002, 46:3843-3845.
76. Athamna A, Massalha M, Athamna M, et al. In vitro susceptibility of Bacillus anthracis to various antibacterial agents and their time-kill activity. J Antimicrob Chemother 2004, 53:247-251.
77. Cavallo J, Ramisse F, Girardet M, et al. Antibiotic susceptibilities of 96 isolates of Bacillus anthracis isolated in France between 1994 and 2000. Antimicrob Agents Chemother 2002, 46:2307-2309.
78. Mohammed M, Marston C, Popovic T, et al. Antimicrobial susceptibility testing of Bacillus anthracis: comparison of results obtained by using the National Committee for Clinical Laboratory Standards broth microdilution reference and Etest agar gradient diffusion methods. J Clin Microbiol 2002, 40:1902-1907.
79. Turnbull P, Sirianni N, LeBron C MICs of selected antibiotics for Bacillus anthracis, Bacillus cereus, Bacillus thuringiensis, and Bacillus mycoides from a range of clinical and environmental sources as determined by the Etest. J Clin Microbiol 2004, 42:3626-3634.
80. Cethromycin: A-195773, A-195773-0, A-1957730, Abbott-195773, ABT 773. Drugs R D 2007, 8:95-102.
81. Ambrose PG, Drusano GL, Craig WA In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans. Clin Infect Dis 2012, 54(suppl 3):S220-S228.
82. Wexselblatt E, Oppenheimer-Shaanan Y, Kaspy I, et al. Relacin, a novel antibacterial agent targeting the Stringent Response. PLoS Pathog 2012, 8.
83. Brook I, Elliott T, Pryor H, et al. In vitro resistance of Bacillus anthracis Sterne to doxycycline, macrolides and quinolones. Int J Antimicrob Agents 2001, 18:559-562.
84. Athamna A, Athamna M, Abu-Rashed N, et al. Selection of Bacillus anthracis isolates resistant to antibiotics. J Antimicrob Chemother 2004, 54:424-428.
85. Inglesby TV, O'Toole T, Henderson DA, et al. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 2002, 287:2236-2252.
86. Hendricks KA, Wright ME, Shadomy SV, et al. Centers for Disease Control and Prevention expert panel meetings on prevention and treatment of anthrax in adults. Emerg Infect Dis 2014, 20. Workgroup on Anthrax Clinical Guidelines.
87. Stern EJ, Uhde KB, Shadomy SV, Messonnier NE Conference report on public health and clinical guidelines for anthrax. Emerg Infect Dis 2008, 14:7-969.
88. Artenstein AW, Opal SM Novel approaches to the treatment of systemic anthrax. Clin Infect Dis 2012, 54:1148-1161.
89. Walsh J, Pesik N, Quinn C, et al. A case of naturally acquired inhalation anthrax: clinical care and analyses of anti-protective antigen immunoglobulin G and lethal factor. Clin Infect Dis 2007, 44:968-971.
90. Klempner MS, Talbot EA, Lee SI, et al. Case records of the Massachusetts General Hospital. Case 25-2010: a 24-year-old woman with abdominal pain and shock. N Engl J Med 2010, 363:766-777.
91. Doust J, Sarkarzadeh A, Kavoossi K Corticosteroid in treatment of malignant edema of chest wall and neck (anthrax). Dis Chest 1968, 53:773-774.
92. Regan J The advantage of serum therapy as shown by comparison of various methods of treatment of anthrax. Am J Med Sci 1921, 162:406-423.
93. Riddle V, Leese P, Blanset D, et al. Phase I study evaluating the safety and pharmacokinetics of MDX-1303, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers. Clin Vaccine Immunol 2011, 18:2136-2142.
94. Subramanian GM, Cronin PW, Poley G, et al. A phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers. Clin Infect Dis 2005, 41:12-20.
95. Froude JW, Stiles B, Pelat T, Thullier P Antibodies for biodefense. MAbs 2011, 3:517-527.
96. Vitale L, Blanset D, Lowy I, et al. Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity. Infect Immun 2006, 74:5840-5847.
97. U.S.Food and Drug Administration Center for Drug Evaluation and Research BLA 125349 raxibacumab for treatment of inhalational anthrax: briefing package to Division of Anti-Infective Products 2012, Human Genome Sciences, Inc, Rockville, MD.
98. Sweeney DA, Hicks CW, Cui X, et al. Anthrax infection. Am J Respir Crit Care Med 2011, 184:1333-1341.
99. Friedlander A, Welkos S, Pitt M Postexposure prophylaxis against experimental inhalation anthrax. J Infect Dis 1993, 167:1239-1242.
100. Mahlandt B, Klein F, Lincoln R, et al. Immunologic studies of anthrax, IV. Evaluation of the immunogenicity of three components of anthrax toxin. J Immunol 1966, 96:727-733.
101. Wright G, Green T, Kanode RJ Studies on immunity in anthrax, V. Immunizing activity of alum-precipitated protective antigen. J Immunol 1954, 73:387-391.
102. Little SF, Knudson GB Comparative efficacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig. Infect Immun 1986, 52:509-512.
103. Wright JG, Quinn CP, Shadomy S, et al. Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2010, 59(RR-6):1-30.
104. Marano N, Plikaytis BD, Martin SW, et al. Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial. JAMA 2008, 300:1532-1543.
105. Grabenstein J Vaccines: countering anthrax: vaccines and immunoglobulins. Clin Infect Dis 2008, 46:129-136.
106. Brachman P, Friedlander A, Grabenstein J Anthrax vaccine. Vaccines 2008, 111-126. Saunders, Philadelphia. S. Plotkin, W. Orenstein, P. Offit (Eds.).
107. Institute of Medicine The Anthrax Vaccine: Is It Safe? Does It Work? 2002, Institute of Medicine, Washington, DC.
108. Sulsky SI, Luippold R, Garman P, et al. Disability among US Army Veterans vaccinated against anthrax. Vaccine 2012, 30:6150-6156.
109. Tierney B, Martin S, Franzke L, et al. Serious adverse events among participants in the Centers for Diseases Control and Prevention's anthrax vaccine and antimicrobial availability program for persons at risk for bioterrorism-related inhalational anthrax. Clin Infect Dis 2003, 37:905-911.
110. Payne D, Rose C, Kerrison J, et al. Anthrax vaccination and risk of optic neuritis in the United States military, 1998-2003. Arch Neurol 2006, 63:871-875.
111. Gorse G, Keitel W, Keyserling H, et al. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA 102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial. Vaccine 2006, 24:5950-5959.
112. Brown BK, Cox J, Gillis A, et al. Phase I study of safety and immunogenicity of an Escherichia coli-derived recombinant protective antigen (rPA) vaccine to prevent anthrax in adults. PLoS One 2010, 5.
113. Campbell JD, Clement KH, Wasserman SS, et al. Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults. Hum Vaccin 2007, 3:205-211.
114. Chabot DJ, Scorpio A, Tobery SA, et al. Anthrax capsule vaccine protects against experimental infection. Vaccine 2004, 23:43-47.
115. Joyce J, Cook J, Chabot D, et al. Immunogenicity and protective efficacy of Bacillus anthracis poly-gamma-d-glutamic acid capsule covalently coupled to a protein carrier using a novel triazine-based conjugation strategy. J Biol Chem 2006, 281:4831-4843.
116. Brossier F, Levy M, Mock M Anthrax spores make an essential contribution to vaccine efficacy. Infect Immun 2002, 70:661-664.
117. Stockholm International Peace Research Institute The rise of CB weapons. The Problem of Chemical and Biological Warfare 1971, Humanities Press, New York.
118. Manchee R, Broster M, Stagg A, et al. Formaldehyde solution effectively inactivates spores of Bacillus anthracis on the Scottish island of Gruinard. Appl Environ Microbiol 1994, 60:4167-4171.
119. Harris S Japanese biological warfare research on humans: a case study of microbiology and ethics. Ann NY Acad Sci 1992, 666:21-52.
120. Meselson M, Guillemin J, Hugh-Jones M, et al. The Sverdlovsk anthrax outbreak of 1979. Science 1994, 266:1202.
121. Cole LA The specter of biological weapons. Sci Am 1996, 275:60-65.
122. Zilinskas RA Iraq's biological weapons: the past as future?. JAMA 1997, 278:418-424.
123. Barakat L, Quentzel H, Jernigan J, et al. Fatal inhalational anthrax in a 94-year-old Connecticut woman. JAMA 2002, 287:863-868.
124. Fennelly K, Davidow A, Miller S, et al. Airborne infection with Bacillus anthracis-from mills to mail. Emerg Infect Dis 2004, 10:996-1001.
125. Canter D Remediating sites with anthrax contamination: building on experience 2003, Presented at the AWMA/EPA Indoor Air Quality Problems and Engineering Solutions Specialty Conference and Exhibition. Research Triangle Park, NC.
126. Stuart A, Wilkening D Degradation of biological weapons agents in the environment: implications for terrorism response. Environ Sci Technol 2005, 39:2736-2743.
127. Weis CP, Intrepido AJ, Miller AK, et al. Secondary aerosolization of viable Bacillus anthracis spores in a contaminated US Senate office. JAMA 2002, 288:2853-2858.
128. Franco C, Sell TK Federal agency biodefense funding, FY2012-FY2013. Biosecur Bioterror 2012, 10:162-181.
129. Layshock JA, Pearson B, Crockett K, et al. Reaerosolization of Bacillus spp. in outdoor environments: a review of the experimental literature. Biosecur Bioterror 2012, 10:299-303.
130. Gottron F CRS Report for Congress: Project Bioshield 2003, The Library of Congress, Washington, DC.
131. U.S.Congress Proliferation of Weapons of Mass Destruction: Assessing the Risks 1993, Office of Technology Assessment, Washington, DC.
132. Bartlett J, Inglesby T, Borio L Management of anthrax. Clin Infect Dis 2002, 35:851-858.
133. Cieslak T, Eitzen E Clinical and epidemiologic principles of anthrax. Emerg Infect Dis 1999, 5:552-555.
134. Hartley DM, Peters CJ Aerosols from insect control measures show dangers of bioterrorism. Biosecur Bioterror 2003, 1:221-222.
135. Levin D, Valadares de Amorim G Potential for aerosol dissemination of biological weapons: lessons from biological control of insects. Biosecur Bioterror 2003, 1:37-42.
136. Lincoln RE, Walker JS, Klein F, et al. Value of field data for extrapolation in anthrax. Fed Proc 1967, 26:1558-1562.
137. Peters CJ, Hartley DM Anthrax inhalation and lethal human infection. Lancet 2002, 359:710-711.
138. Brachman PS, Kaufman AF, Dalldorf FG Industrial inhalation anthrax. Bacteriol Rev 1966, 30:646-659.
139. Carr E, Rew R Recovery of Bacillus anthracis from the nose and throat of apparently healthy workers. J Infect Dis 1957, 100:169-171.
140. Dahlgren C, Buchanan L, Decker H, et al. Bacillus anthracis aerosols in goat hair processing mills. Am J Hyg 1960, 72:24-31.
141. Doolan DL, Freilich DA, Brice GT, et al. The US Capitol bioterrorism anthrax exposures: clinical epidemiological and immunological characteristics. J Infect Dis 2007, 195:174-184.
142. Brachman PS Inhalation anthrax. Ann N Y Acad Sci 1980, 353:83-93.
143. Kournikakis B, Armour S, Boulet C, et al. Technical Report: Risk Assessment of Anthrax Threat Letters 2001, Defence Research Establishment-Suffield, Ralston, Alberta.
144. Kournikakis B, Ho J Objective assessment of the hazard from anthrax terrorist attacks in an office environment. Anthrax Incident Management Workshop 2002, Defence R&D Canada-Suffield, Medicine Hat, Alberta.
145. Hoover M Uncertainty and probability distribution analyses for anthrax dispersion and human exposure. Anthrax Incident Management Workshop 2002, Defence R&D Canada, Medicine Hat, Alberta.
146. Wein LM, Craft DL, Kaplan EH Emergency response to an anthrax attack. Proc Natl Acad Sci U S A 2003, 100:4346-4351.
147. Buckeridge DL, Owens DK, Switzer P, et al. Evaluating detection of an inhalational anthrax outbreak. Emerg Infect Dis 2006, 12:1942-1949.
148. Bush LM, Perez MT The anthrax attacks 10 years later. Ann Intern Med 2012, 156:41-44.
149. Russell PK, Gronvall GK U.S. medical countermeasure development since 2001: a long way yet to go. Biosecur Bioterror 2012, 10:66-76.
150. Centers for Disease Control and Prevention Notice to readers: considerations for distinguishing influenza-like illness from inhalational anthrax. MMWR Morb Mortal Wkly Rep 2001, 50:984-986.
151. Kuehnert MJ, Doyle TJ, Hill HA, et al. Clinical features that discriminate inhalational anthrax from other acute respiratory illnesses. Clin Infect Dis 2003, 36:328-336.
152. Kyriacou D, Stein A, Yarnold P, et al. Clinical predictors of bioterrorism-related inhalational anthrax. Lancet 2004, 364:449-452.
153. Dixon TC, Meselson M, Guillemin J, et al. Anthrax. N Engl J Med 1999, 341:815-826.
154. Wood BJ, DeFranco B, Ripple M, et al. Inhalational anthrax: radiologic and pathologic findings in two cases. AJR Am J Roentgenol 2003, 181:1071-1078.
155. Selinsky CL, Whitlow VD, Smith LR, et al. Qualification and performance characteristics of a quantitative enzyme-linked immunosorbent assay for human lgG antibodies to anthrax lethal factor antigen. Biologicals 2007, 35:123-129.
156. Boyer AE, Quinn CP, Woolfitt AR, et al. Detection and quantification of anthrax lethal factor in serum by mass spectrometry. Anal Chem 2007, 79:8463-8470.
157. Kozel TR, Murphy WJ, Brandt S, et al. mAbs to Bacillus anthracis capsular antigen for immunoprotection in anthrax and detection of antigenemia. Proc Natl Acad Sci U S A 2004, 101:5042-5047.
158. Centers for Disease Control and Prevention Update: Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. MMWR Morb Mortal Wkly Rep 2001, 50:909-919.
159. Shepard CW, Soriano-Gabarro M, Zell ER, et al. Anti-microbial postexposure prophylaxis for anthrax: adverse events and adherence. Emerg Infect Dis 2002, 8:1124-1132.
160. Heine H, Bassett J, Miller L, et al. Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax. Antimicrob Agents Chemother 2008, 52:3350-3357.
161. Quinn CP, Sabourin CL, Niemuth NA, et al. A three-dose intramuscular injection schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long-term protection against inhalation anthrax in rhesus macaques. Clin Vaccine Immunol 2012, 19:1730-1745.
162. Vietri N, Purcell B, Lawler J, et al. Short-course postexposure antibiotic prophylaxis combined with vaccination protects against experimental inhalational anthrax. Proc Natl Acad Sci USA 2006, 102:7813-7816.
163. Bielinska AU, Janczak KW, Landers JJ, et al. Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge. Infect Immun 2007, 75:4020-4029.
164. Hannesschlager JR Results of a safety and immunogenicity study of an early-stage investigational rPA102 vaccine as compared to the FDA licensed anthrax vaccine (anthrax vaccine adsorbed (AVA. BioThrax)). Vaccine 2007, 25:3247.
165. Zhang J, Jex E, Feng T, et al. An adenovirus-vectored nasal vaccine confers rapid and sustained protection against anthrax in a single-dose regimen. Clin Vaccine Immunol 2013, 20:1-8.
166. Friedlander A Anthrax: clinical features, pathogenesis, and potential biological warfare threat. Curr Clin Top Infect Dis 2000, 20:335-349.
167. Campbell CG, Kirvel RD, Love AH, et al. Decontamination after a release of B. anthracis spores. Biosecur Bioterror 2012, 10:108-122.
168. National Research Council Reopening Public Facilities after a Biological Attack: A Decision-Making Framework 2005, The National Academies Press, Washington, DC.
169. Turnbull P, Sirianni N, LeBron C MICS of selected antibiotics for Bacillus anthracis, Bacillus cereus, Bacillus thuringiensis and Bacillus mycoides from a range of clinical and environmental sources as determined by the Etest. J Clin Microbiol 2004, 42:3626-3634.
170. Abramova F, Grinberg L, Yamplskaya O, Walker D Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proc Natl Acad Sci U S A 1993, 90:2291-2294.
171. World Health Organization Anthrax Data Site Available at, Accessed January 11, 2013. http://www.vetmed.lsu.edu/whocc/mp_world.htm.
172. Centers for Disease Control and Prevention Gastrointestinal anthrax after an animal-hide drumming event-New Hampshire and Massachusetts, 2009. MMWR Morb Mortal Wkly Rep 2010, 59:872-877.
173. Palmateer NE, Ramsay CN, Browning L, et al. Anthrax infection among heroin users in Scotland during 2009-2010: a case-control study by linkage to a national drug treatment database. Clin Infect Dis 2012, 55:706-710.
174. American Society for Microbiology, Centers for Disease Control and Prevention, and Association of Public Health Laboratories Sentinel Level Clinical Microbiology Laboratory Guidelines for Suspected Agents of Bioterrorism and Emerging Infectious Diseases-Bacillus anthracis 2010, American Society for Microbiology, Washington, DC.
175. Center for Infectious Disease Research and Policy Anthrax: Clinical Laboratory Testing Available at, Accessed January 21, 2013. http://www.cidrap.umn.edu/cidrap/content/bt/anthrax/biofacts/index.html.
176. Glassman H Discussion-industrial inhalation anthrax. Bacteriol Rev 1966, 30:657-659.
177. Gochenour W, Sawyer W, Henderson J, et al. On the recognition and therapy of simian woolsorter's disease. J Hyg 1963, 61:317-322.
178. Henderson D, Peacock S, Belton F Observations on the prophylaxis of experimental pulmonary anthrax in the monkey. J Hyg 1956, 54:28-36.
179. American Society for Microbiology Sentinel Laboratory Guidelines for Suspected Agents of Bioterrorism and Emerging Infections Diseases Packing and Shipping Infectious Substances Available at, Accessed February 12, 2013. http://www.asm.org/index.php/issues/sentinel-laboratory-guidelines.
180. Gold H Anthrax, a report of one hundred seventeen cases. Arch Intern Med 1955, 96:387-396.
181. American College of Physicians Anthrax Available at, Accessed January 21, 2013. http://pier.acponline.org/physicians/public/d892/d892.html.
182. De BK, Bragg SL, Sanden GN, et al. A two-component direct fluorescent-antibody assay for rapid identification of Bacillus anthracis. Emerg Infect Dis 2002, 8:1060-1065.
183. Hoffmaster AR, Meyer RF, Bowen MD, et al. Evaluation and validation of a real-time polymerase chain reaction assay for rapid identification of Bacillus anthracis. Emerg Infect Dis 2002, 8:1178-1182.
184. Holty J, Bravata D, Liu H, et al. Systematic review: a century of inhalational anthrax cases from 1900 to 2005. Ann Intern Med 2006, 144:270-280.
185. Plotkin S, Brachman P, Utell M, et al. An epidemic of inhalation anthrax, the first in the twentieth century. Am J Med 1960, 29:992-1001.
186. Norman P, Ray J, Brachman P, et al. Serological testing for anthrax antibodies in workers in a goat hair processing mill. Am J Hyg 1960, 72:32-37.
187. Brookmeyer R, Johnson E, Bollinger R Modeling the optimum duration of antibiotic prophylaxis in an anthrax outbreak. Proc Natl Acad Sci U S A 2003, 100:10129-10132.
188. Vietri NJ, Purcell BK, Tobery SA, et al. A short course of antibiotic treatment is effective in preventing death from experimental inhalational anthrax after discontinuing antibiotics. J Infect Dis 2009, 199:336-341.
189. Migone TS, Subramanian GM, Zhong J, et al. Raxibacumab for the treatment of inhalational anthrax. N Engl J Med 2009, 361:135-144.
190. Fine A, Wong J, Fraser H, et al. Is it influenza or anthrax? A decision analytic approach to the treatment of patients with influenza-like illnesses. Ann Emerg Med 2004, 43:318-328.
191. Borio L, Frank D, Mani V, et al. Death due to bioterrorism-related inhalational anthrax. JAMA 2001, 286:2554-2559.
192. Jernigan J, Stephens D, Ashford D, et al. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis 2001, 7:933-943.
193. Sirisanthana T, Brown A Anthrax of the gastrointestinal tract. Emerg Infect Dis 2002, 8:649-651.
194. Sejvar J, Tenover F, Stephens D Management of anthrax meningitis. Lancet Infect Dis 2005, 5:287-295.
195. Athamna A, Massalha M, Athamna M, et al. In vitro susceptibility of Bacillus anthracis to various antibacterial agents and their time-kill activity. J Antimicrob Chemother 2004, 53:247-251.
196. Cavallo J, Ramisse F, Girardet M, et al. Antibiotic susceptibilities of 96 isolates of Bacillus anthracis isolated in France between 1994 and 2000. Antimicrob Agents Chemother 2002, 46:2307-2309.
197. Turnbull P, Sirianni N, LeBron C MICs of selected antibiotics for Bacillus anthracis, Bacillus cereus, Bacillus thuringiensis, and Bacillus mycoides from a range of clinical and environmental sources as determined by the Etest. J Clin Microbiol 2004, 42:3626-3634.
198. Inglesby TV, O'Toole T, Henderson DA, et al. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 2002, 287:2236-2252.
199. Hendricks KA, Wright ME, Shadomy SV, et al. Centers for Disease Control and Prevention expert panel meetings on prevention and treatment of anthrax in adults. Emerg Infect Dis 2014, 20. Workgroup on Anthrax Clinical Guidelines.
200. Artenstein AW, Opal SM Novel approaches to the treatment of systemic anthrax. Clin Infect Dis 2012, 54:1148-1161.
201. Froude JW, Stiles B, Pelat T, Thullier P Antibodies for biodefense. MAbs 2011, 3:517-527.
202. U.S.Food and Drug Administration Center for Drug Evaluation and Research BLA 125349 raxibacumab for treatment of inhalational anthrax: briefing package to Division of Anti-Infective Products 2012, Human Genome Sciences, Inc, Rockville, MD.
203. Friedlander A, Welkos S, Pitt M Postexposure prophylaxis against experimental inhalation anthrax. J Infect Dis 1993, 167:1239-1242.
204. Wright JG, Quinn CP, Shadomy S, et al. Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2010, 59(RR-6):1-30.
205. Marano N, Plikaytis BD, Martin SW, et al. Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial. JAMA 2008, 300:1532-1543.
206. Meselson M, Guillemin J, Hugh-Jones M, et al. The Sverdlovsk anthrax outbreak of 1979. Science 1994, 266:1202.
207. Barakat L, Quentzel H, Jernigan J, et al. Fatal inhalational anthrax in a 94-year-old Connecticut woman. JAMA 2002, 287:863-868.
208. Weis CP, Intrepido AJ, Miller AK, et al. Secondary aerosolization of viable Bacillus anthracis spores in a contaminated US Senate office. JAMA 2002, 288:2853-2858.
209. Bartlett J, Inglesby T, Borio L Management of anthrax. Clin Infect Dis 2002, 35:851-858.
210. Cieslak T, Eitzen E Clinical and epidemiologic principles of anthrax. Emerg Infect Dis 1999, 5:552-555.
211. Brachman PS, Kaufman AF, Dalldorf FG Industrial inhalation anthrax. Bacteriol Rev 1966, 30:646-659.
212. Carr E, Rew R Recovery of Bacillus anthracis from the nose and throat of apparently healthy workers. J Infect Dis 1957, 100:169-171.
213. Dahlgren C, Buchanan L, Decker H, et al. Bacillus anthracis aerosols in goat hair processing mills. Am J Hyg 1960, 72:24-31.
214. Doolan DL, Freilich DA, Brice GT, et al. The US Capitol bioterrorism anthrax exposures: clinical epidemiological and immunological characteristics. J Infect Dis 2007, 195:174-184.
215. Kournikakis B, Ho J Objective assessment of the hazard from anthrax terrorist attacks in an office environment. Anthrax Incident Management Workshop 2002, Defence R&D Canada-Suffield, Medicine Hat, Alberta.
216. Wein LM, Craft DL, Kaplan EH Emergency response to an anthrax attack. Proc Natl Acad Sci U S A 2003, 100:4346-4351.
217. Centers for Disease Control and Prevention Notice to readers: considerations for distinguishing influenza-like illness from inhalational anthrax. MMWR Morb Mortal Wkly Rep 2001, 50:984-986.
218. Kuehnert MJ, Doyle TJ, Hill HA, et al. Clinical features that discriminate inhalational anthrax from other acute respiratory illnesses. Clin Infect Dis 2003, 36:328-336.
219. Kyriacou D, Stein A, Yarnold P, et al. Clinical predictors of bioterrorism-related inhalational anthrax. Lancet 2004, 364:449-452.
220. Dixon TC, Meselson M, Guillemin J, et al. Anthrax. N Engl J Med 1999, 341:815-826.
221. Wood BJ, DeFranco B, Ripple M, et al. Inhalational anthrax: radiologic and pathologic findings in two cases. AJR Am J Roentgenol 2003, 181:1071-1078.
222. Boyer AE, Quinn CP, Woolfitt AR, et al. Detection and quantification of anthrax lethal factor in serum by mass spectrometry. Anal Chem 2007, 79:8463-8470.
223. Centers for Disease Control and Prevention Update: Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. MMWR Morb Mortal Wkly Rep 2001, 50:909-919.
224. Shepard CW, Soriano-Gabarro M, Zell ER, et al. Antimicrobial postexposure prophylaxis for anthrax: adverse events and adherence. Emerg Infect Dis 2002, 8:1124-1132.
225. Vietri N, Purcell B, Lawler J, et al. Short-course postexposure antibiotic prophylaxis combined with vaccination protects against experimental inhalational anthrax. Proc Natl Acad Sci USA 2006, 102:7813-7816.
226. Friedlander A Anthrax: clinical features, pathogenesis, and potential biological warfare threat. Curr Clin Top Infect Dis 2000, 20:335-349.